INGREDIENT INSIGHTS
SEM in Chondroitin Sulfate: Why Buyers Should Pay Attention
Interpreting semicarbazide results without confusing detection, origin and regulatory action.
Semicarbazide, usually abbreviated SEM, deserves attention in chondroitin sulfate qualification because its detection can raise questions about raw materials, processing and regulatory compliance. A chondroitin assay does not answer those questions: SEM requires a separate analytical assessment.
The central distinction is that detecting SEM does not, by itself, establish how it entered the material. Buyers should investigate the finding, confirm that the method is suitable and assess the legal requirements for the actual product category.
Quick Links:
1. What SEM represents
SEM is used as a marker associated with nitrofurazone, a non-allowed veterinary drug in food-producing animals in the EU residue-control context. However, research has demonstrated other routes of formation. Experiments found that hypochlorite treatment could generate SEM in certain nitrogen-containing materials. These results establish a possible processing pathway; they do not prove the cause of an individual chondroitin result. [1]
Two shortcuts should therefore be avoided: assuming that every SEM finding proves illegal veterinary treatment, and assuming that every finding can be explained away as processing-related. Both conclusions require evidence.
2. Understand the European reference point for action
Regulation (EU) 2019/1871 establishes reference points for action, or RPAs, for non-allowed pharmacologically active substances. Its nitrofuran entry includes a value of 0.5 μg/kg for each listed marker. An RPA is an enforcement reference point, not an authorised residue allowance or a general toxicological safety threshold. [2]
The amendment in Regulation (EU) 2024/2858 provides special conditions for SEM in listed processed products, including hydrolysed cartilage products. For these categories, application of the SEM RPA is conditional on established illegal use, linked in the provision to detection of another nitrofuran metabolite. [3]
Do not assume that every product sold as chondroitin sulfate automatically falls within that category. Establish the classification and applicable interpretation for the actual material. A supplier’s broad statement that “SEM is exempt” is insufficient. Regulatory context reviewed on 27 October 2026.
3. Ask what the laboratory actually measured
Request the full laboratory report rather than a COA line reading “SEM free.” The report should identify the sample and batch, method, units, result, reporting limit and laboratory.
A suitable confirmatory approach commonly uses liquid chromatography with tandem mass spectrometry. Ask how the method has been verified for chondroitin and how matrix effects, recovery and analytical identification are controlled. Clarify the sample preparation and whether the result concerns free SEM, a bound fraction or a broader method-defined quantity. Results obtained using different preparations may not be directly comparable.
Also ask whether other relevant nitrofuran markers were analysed. Their results may be important to an investigation and to interpretation of the applicable regulatory provision; they should not be inferred from the SEM result alone.
4. Read units and reporting limits carefully
For a mass fraction in a solid, 0.5 μg/kg equals 0.0005 mg/kg. Confusing these units creates a thousandfold error.
“Not detected” means below a defined detection or reporting capability, not zero. If a buyer’s contractual criterion is 0.5 μg/kg and the report states only <1.0 μg/kg, the result does not demonstrate compliance with that criterion. This example illustrates reporting sensitivity, not an assertion that the same legal limit applies to every chondroitin product.
Agree the method, reporting threshold and decision rule before testing. A “pass” without these details is difficult to interpret.
5. Investigate source and process together
A useful investigation compares raw-material records, process information and results from relevant stages. Ask about the use of oxidants, bleaching agents or disinfectants and how contact, rinsing and carry-over are controlled. A possible chemical pathway is a hypothesis to investigate, not proof of supplier misconduct.
Where justified, analyse retained samples, incoming material or intermediate fractions. Preserve the connection between each sample and the affected batch. Review other marker results and independent laboratory confirmation when needed.
Keep the material under quality hold while unresolved findings prevent a reliable release decision. Do not repeatedly test until a favourable value appears or blend a questionable lot merely to lower the reported concentration.
6. Define a practical control plan
|
Control point
|
Evidence to request
|
Purpose
|
|---|---|---|
|
Initial qualification
|
Process description and relevant residue assessment
|
Identify plausible sources of SEM
|
|
Laboratory suitability
|
Matrix verification and reporting limits
|
Ensure the test answers the question
|
|
Batch interpretation
|
SEM and relevant marker results
|
Support an informed investigation
|
|
Regulatory review
|
Documented product classification
|
Avoid applying an exception too broadly
|
|
Corrective action
|
Root-cause findings and effectiveness checks
|
Demonstrate sustained control
|
Testing frequency should reflect source risk, process knowledge, historical results and customer requirements. A contractual limit can be more restrictive than a regulatory action framework, but the two should be clearly distinguished.
Conclusion
The animal origin of chondroitin sulfate is best assessed through connected evidence: a precise source claim, reliable traceability and appropriate analytical verification.
A high assay does not prove species identity, a negative DNA result does not prove absolute absence, and a characteristic structural profile is not automatically unique to one animal. Reliable conclusions state what the evidence supports and where its limits remain.
